Indefinite Delivery Contract 75D30126D21003

The Centers for Disease Control and Prevention, on behalf of its Office of Acquisition Services, awarded an indefinite-delivery, multiple-award contract to Moderna US, Inc. with a ceiling value of $29,183,000 and an award date of June 1, 2026. The contract runs through May 31, 2027.

The solicitation, posted March 4, 2026 with proposals due March 17, 2026, sought FDA-approved COVID-19 vaccines for adults aged 19 and older to support the Section 317 immunization program, which distributes vaccines to state and local health departments across the fifty states, large city programs, and U.S. Territories. Offerors submitted firm-fixed pricing proposals compliant with Federal Excise Tax requirements ($0.75 per dose) and not exceeding the manufacturer's Federal Ceiling Price. Vaccines must have a minimum 12-month shelf life upon delivery and be manufactured under current FDA establishment and product licenses in compliance with Current Good Manufacturing Practice Regulations. Minimum order size is 100 doses per delivery order; maximum is 10 million doses per vaccine offering. Deliveries are required within 15 working days of order placement through the Vaccine Tracking System. Delivery occurs F.O.B. destination to CDC centralized distribution locations in Olive Branch, Mississippi and Clermont, Kentucky, and to five CDC Occupational Health Clinic locations as directed. The place of performance is Chamblee, Georgia, with contract activities coordinated through the CDC's Office of Acquisition Services in Atlanta, Georgia. The combined maximum contract value across all awards under this program is $892,363,500. Non-small business offerors were required to submit acceptable subcontracting plans with targets including 9.37% small business participation, 2.17% small disadvantaged business, 0.70% HUBZone, 1.44% women-owned small business, and 2.33% service-disabled veteran-owned small business.